Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
1/9/25 | Sanofi (SNY) | Sarclisa for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
1/8/25 | LB Pharmaceuticals | LB-102 for Schizophrenia | Subscribers Only | Subscribers Only | Subscribers Only |
1/7/25 | Metsera | MET-097i for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
1/6/25 | PharmaEssentia (6446) | Besremi for Essential Thrombocythemia (ET) | Subscribers Only | Subscribers Only | Subscribers Only |
1/2/25 | Neumora Therapeutics (NMRA) | Navacaprant for Major Depressive Disorder (MDD) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
09/12/2024 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
10/16/2024 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
10/30/2024 | Subscribers Only | Subscribers Only | Progress Update - Development Review |
11/15/2024 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
11/19/2024 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |